AbbVie Acquisition +4.5%: AbbVie Bets Big on Apogee
Is AbbVie’s $10.9 billion Apogee deal a bold immunology masterstroke, or an expensive bet on future growth? Maik Kemper Editor in Chief The acquisition of Apogee further builds…
AbbVie Dermatology Data Boom at AAD 2026 Shocks Investors
Can AbbVie’s latest dermatology data at AAD 2026 really secure its post-Humira growth story in immunology? Maik Kemper Editor in Chief Our robust evidence across multiple clinical trials…
Johnson & Johnson FDA approval ICOTYDE Boom Explained
Can Johnson & Johnson’s FDA approval of ICOTYDE really shift the psoriasis market enough to move a $575 billion healthcare giant? Maik Kemper Editor in Chief ICOTYDE delivers…